Outcomes-Based Agreements Give New Insight for Treatment of Diabetes and Cardiovascular Disease

This AJMC^® Profiles in Care provides an in-depth look into the results of the innovative outcomes-based agreement between Boehringer Ingelheim and Highmark Inc that focused on total cost of care for patients with type 2 diabetes and cardiovascular disease. An overview of the results, as well as valuable insights from experts from Boehringer Ingelheim and Highmark, are included.

Download PDF: Outcomes-Based Agreements Give New Insight for Treatment of Diabetes and Cardiovascular Disease

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Outcomes-Based Agreements Give New Insight for Treatment of Diabetes and Cardiovascular Disease

Related Content

Nurse-Delivered Telehealth Falls Short for Diabetes in Fee-for-Service Trial

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Telemedicine Diabetes Clinic Cuts HbA1c in Incarcerated Men

Evolocumab Cuts MACE by 29% in High-Risk Diabetes Without Prior MI or Stroke: Lawrence Leiter, MD

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Trending on AJMC

COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV

New Bill Would Cap Traditional Medicare Out-of-Pocket Costs at $5000

Topical Delgocitinib Improves Chronic Hand Eczema Outcomes Across All Trial Timepoints

COA Offers Playbook to Help Community Oncology Practices Navigate AI Partnerships

Community Oncology Must Adapt for CAR T, Bispecific Multiple Myeloma Care: Mohit Narang, MD